1. Travel-Associated Health Risks for Patients With Inflammatory Bowel Disease 
Shomron Ben–Horin, Yoram Bujanover, Shulamit Goldstein, Moshe Nadler, Alon Lang, Uri Kopylov, Lior Katz, Adi Lahat, Eli Schwartz, Benjamin Avidan 
Clinical Gastroenterology and Hepatology 
Volume 10, Issue 2, Pages e1 (February 2012)
DOI: /j.cgh
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1
The rate of illness during trips in the IBD and healthy control populations, stratified by countries of destinations. By definition, developing countries also include tropical countries, but the latter are also shown separately in the bars on the right for finer data presentation.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2012 AGA Institute Terms and Conditions

3. Figure 2
The distribution of the immunomodulating drugs used regularly during the trips by IBD patients.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2012 AGA Institute Terms and Conditions

4. Supplementary Figure 1
The rate of illness during travel in the immunosuppressed or immunocompetent IBD and healthy control populations.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2012 AGA Institute Terms and Conditions